Cleared Traditional

PRIZM BLADE (MORIA MODEL) LSK / MK8510LSK (K011195) - FDA 510(k) Clearance

Also marketed or referenced as:
PRIZM BLADE (MORIA MODEL) CB / MK8511CB

Class I Ophthalmic device.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2001
Decision
201d
Days
Class 1
Risk

K011195 is an FDA 510(k) clearance for the PRIZM BLADE (MORIA MODEL) LSK / MK8510LSK. Classified as Keratome, Ac-powered (product code HNO), Class I - General Controls.

Submitted by Surgin Surgical Instrumentation, Inc. (Tustin, US). The FDA issued a Cleared decision on November 6, 2001 after a review of 201 days - an extended review cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4370 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Ophthalmic review framework, consistent with the majority of Class II 510(k) submissions.

View all Surgin Surgical Instrumentation, Inc. devices

Submission Details

510(k) Number K011195 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 19, 2001
Decision Date November 06, 2001
Days to Decision 201 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
91d slower than avg
Panel avg: 110d · This submission: 201d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code HNO Keratome, Ac-powered
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 886.4370
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.